Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million … Continue reading Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the day at $98.42. Traded volume was 10.31million shares in the … Continue reading Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

Israel-based Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) has announced that the U.S. Supreme Court has granted the Company’s Copaxone certiorari petition, and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was 1.39% in last session and finished the day … Continue reading Healthcare Active runners: Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co (NYSE:MRK), Sanofi (NYSE:SNY)

Three years after Pfizer Inc. (NYSE:PFE) announced more than 1,000 layoffs that Gov. Dannel P. Malloy at the time called “terrible news,” the pharmaceutical company and the state said Wednesday they’ve come up with new uses for the Groton site. Malloy and top officials of his administration and Pfizer Inc (NYSE:PFE) said two vacant buildings on the company’s campus will be used for bioscience research … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY)

Merck & Co., Inc. (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. Merck … Continue reading Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. Pfizer Inc. (NYSE:PFE) stock performance was 1.05% in last session and finished the day at $31.82. Traded volume was 21.09million shares in the last session and the average volume of the stock remained … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK)